The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy
|
|---|---|
| Published in |
Frontiers in oncology, August 2015
|
| DOI | 10.3389/fonc.2015.00186 |
| Pubmed ID | |
| Authors |
Jonathan Noujaim, Khin Thway, Zia Bajwa, Ayeza Bajwa, Robert G. Maki, Robin L. Jones, Charles Keller |
| Abstract |
Epithelioid sarcoma (ES) is a soft tissue sarcoma of children and young adults for which the preferred treatment for localized disease is wide surgical resection. Medical management is to a great extent undefined, and therefore for patients with regional and distal metastases, the development of targeted therapies is greatly desired. In this review, we will summarize clinically relevant biomarkers (e.g., SMARCB1, CA125, dysadherin, and others) with respect to targeted therapeutic opportunities. We will also examine the role of EGFR, mTOR, and polykinase inhibitors (e.g., sunitinib) in the management of local and disseminated disease. Toward building a consortium of pharmaceutical, academic, and non-profit collaborators, we will discuss the state of resources for investigating ES with respect to cell line resources, tissue banks, and registries so that a roadmap can be developed toward effective biology-driven therapies. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 51 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 19% |
| Student > Doctoral Student | 6 | 11% |
| Other | 5 | 9% |
| Student > Bachelor | 4 | 8% |
| Student > Ph. D. Student | 4 | 8% |
| Other | 9 | 17% |
| Unknown | 15 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 40% |
| Biochemistry, Genetics and Molecular Biology | 4 | 8% |
| Agricultural and Biological Sciences | 3 | 6% |
| Mathematics | 1 | 2% |
| Decision Sciences | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 20 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2015.
All research outputs
#15,168,167
of 25,371,288 outputs
Outputs from Frontiers in oncology
#4,543
of 22,414 outputs
Outputs of similar age
#135,674
of 277,783 outputs
Outputs of similar age from Frontiers in oncology
#17
of 59 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,414 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,783 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.